Table of Contents - WOC 2012

WOC2012 Abstract Book
IS-ONC-MO 359 (2)
Brachytherapy
Singh Arun (1)
1. Cole Eye Institute
Brachytherapy is the most frequently used treatment for uveal melanoma. The
presentation will include surgical technique (video), data regarding tumor
control, and complications. Recent innovation in plaque design and dosimertry
will also be presented.
IS-ONC-MO 359 (3)
Surgery
Damato Bertil (1)
1. Royal Liverpool University Hospital
Methods of local resection of uveal melanoma include: iridectomy; iridocyclectomy;
trans-scleral choroidectomy; trans-scleral cyclo-choroidectomy;
and trans-retinal endoresection. Primary local resection is indicated when
the tumour is considered unsuitable for radiotherapy and/or phototherapy.
Secondary tumour resection is useful for recurrence after radiotherapy and
for exudation from an irradiated tumour (‹toxic tumour syndrome›). Tumour
resection is a valuable addition to the current range of therapeutic modalities,
often providing the best or the only method of conserving the eye with useful
vision.
IS-ONC-MO 359 (4)
Proton Beam Radiotherapy
Gragoudas Evangelos (1)
1.
Uveal melanoma is a rare intraocular malignancy. The current standard of care
for most tumors is radiotherapy. Proton irradiation offers the advantage of highly
localized and uniform dose distributions, which may optimize local control and
minimize complications. Long-term outcomes in a large series of patients
treated with proton irradiation for uveal melanoma at the Massachusetts Eye
and Ear Infirmary will be reviewed, and data to assist the ocular oncologist in
making recommendations for treatment will be presented.
IS-ONC-MO 359 (5)
Screening for Metastases
Pe’er Jacob
Uveal melanoma is the most common primary intraocular tumor in adults, and
the liver is the main target organ of metastases. The traditional methods of
screening for metastases have been liver imaging, chest X-ray, and liver
function tests. The yield of the latter two was proven to be very low; thus, liver
imaging such as ultrasound, CT and MRI are commonly used. Recently, PET-
CT was suggested as a means of imaging. Some centers have begun using
serum biomarkers for early detection of metastatic disease.
IS-ONC-MO 359 (6)
Disseminated Disease
Seregard Stefan (1)
342
(1)
1. Hadassah-Hebrew University Medical Center
1. Department of Vitroretinal Disease, St Eriks Eye Hospital
Nearly half of patients with uveal melanoma develop disseminated disease. In
an early stage tumour seeding may be confined to the liver making this an
interesting target for treatment. Clinical effects have so far been minimal, but
preliminary results from new research avenues suggest that this may change
in a not too distant future. This overview will outline what may come ahead.
Tissue Bioengineering and Regeneration
Mon 20 Feb 8:30 - 10:00 Conference Room B2
IS-TEC-MO 360 (1)
Applications of Nanotechnology in Ophthalmology
Leary James (1)
1. Purdue University
This general overview talk will introduce nanotechnology developments
applicable to ophthalmology. Nanotechnology is being developed for a wide
variety of applications in ophthalmology, including controlled drug delivery
both within the eye using nanoparticles and through nanopore channels using
contact lenses for steady-state drug delivery, nanomedical approaches to
reducing oxidative stress damage to the retina and the optic nerve, implants for
artificial vision, and light-activated nanowires for treatment of retinal ischemia.
IS-TEC-MO 360 (2)
Fundamental Issues in Stem Cell Transplantation of the Ocular
Surface
Kruse Friedrich (1)
1. Department of Ophthalmology, University of Erlangen-Nuremberg
Abstract not available
IS-TEC-MO 360 (3)
Epithelial Corneal Dystrophy
Moore Johnny (1,2)
1. University of Ulster /
2. University of Dundee
Meesmanns corneal dystrophy is a relatively benign rare corneal disorder
confined to the anterior epithelium. We use this as a model to determine the
specificity and potency of treatment with siRNA designed to knock down the
mutant allele, while allowing the normal allele to restore a healthy ocular surface.
This is a particularly tractable model for the application of gene therapy for
other corneal dystrophies with similar dominant negative pathomechanisms.
IS-TEC-MO 360 (4)
Transplantation of Retinal Pigment Epithelium Derived from iPS Cells
Okamoto Satoshi (1)
1. RIKEN Center for Developmental Biology
Age-related macular degeneration (AMD) is a disease caused by the
senescence of retinal pigment epithelial (RPE) cells. However, currently there is
no effective therapy for RPE damage. We have succeeded to induce RPE from
human ES/iPS cells that can be used for regenerative therapy. Transplantation
of RPE will improve the symptom or repress the progression of the disease. In
this presentation, I will introduce our latest research and development of RPE
transplantation therapy for AMD patients.
IS-TEC-MO 360 (5)
The Use of Induced Pluripotent Stem Cells (iPS) in Corneal Tissue
Engineering
Shimmura Shigeto (1)
1. Keio University School of Medicine
Induced pluripotent stem cells (iPS cells) are a new source of stem cells. We
successfully induced stratified epithelial cells from mouse iPS cells by coculture
with PA6 feeder cells and BMP4. We cloned cytokeratin 14 and p63
double-positive stratified epithelial progenitor cells from iPS-derived epithelial
cells, and engineered stratified epithelial sheets consisting of 5 to 6 layers
of polarized epithelial cells. Electron microscopy revealed microvilli on the
surface of epithelial sheets that were similar to murine corneal epithelial cells.
When these clonal cells were cultured on denuded mouse corneas, a robust
stratified epithelial layer was observed with high levels of E-cadherin, p63
and K15 expression in the basal layer. Studies to produced similar cells from
human iPS cells are underway.